[Pharmacology of neurodegenerative diseases: perspectives on cellular and gene therapies]
Related Experiment Video
Updated: Oct 28, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
1Rhône Poulenc Rorer, Vitry sur Seine, France.
Therapie
|October 17, 1998
Abstract:
Treatment of degenerative diseases includes neuroprotective strategies. Among these, the importance of the different neurotrophic factors has been demonstrated but the remaining difficulty is the way of administration. It is important to find new strategies in cell and gene domains. Cell ex vivo therapy and gene in vivo therapy are under development but must be confirmed by clinical trials.
Insights
New neuroprotective strategies for degenerative diseases focus on neurotrophic factors. Cell ex vivo and gene in vivo therapies are promising but require clinical validation.
Area of Science:
- Neuroscience
- Biomedical Engineering
Context:
- Degenerative diseases pose significant therapeutic challenges.
- Neuroprotective strategies are crucial for managing neurodegeneration.
- Neurotrophic factors show therapeutic potential but face delivery hurdles.
Purpose:
- To explore novel neuroprotective strategies for degenerative diseases.
- To address the challenge of delivering neurotrophic factors effectively.
- To investigate advancements in cell and gene therapy domains.
Summary:
- The study highlights the importance of neurotrophic factors in treating degenerative diseases.
- Current research focuses on overcoming delivery challenges associated with these factors.
- Cell ex vivo and gene in vivo therapies are emerging as potential solutions, requiring further clinical trials.
Impact:
- Advances in cell and gene therapy could revolutionize degenerative disease treatment.
- Successful clinical trials will validate new therapeutic avenues.
- Improved delivery methods for neurotrophic factors may enhance patient outcomes.
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...